Here's what we'll cover
Here's what we'll cover
Why a Drugmaker Is Calling for Subsidies (and Why That Should Interest You)
It might seem unusual for a pharmaceutical company to lobby for government subsidies on its own products. But Novo Nordisk, the maker of Ozempic and Wegovy, is doing exactly that, calling on governments to fund targeted access to GLP-1 weight-loss medications for patients who need them most.
This is not purely altruistic. Broader coverage means more patients, which means more revenue. But the underlying argument has real merit for patients: GLP-1 drugs like semaglutide have demonstrated meaningful benefits for people with serious obesity-related health conditions, and cost remains the single biggest barrier to access.
If you are currently paying out of pocket or fighting with insurance, this policy push matters to you. Here is what targeted subsidies would actually mean and how to think about your situation while the debate plays out.
What "Targeted" Subsidies Actually Means
The word "targeted" is doing a lot of work in this conversation. Novo Nordisk is not calling for blanket, universal coverage of GLP-1 medications for anyone who wants to lose a few pounds. The proposal is more focused than that.
Who Would Likely Qualify Under a Targeted Model
Targeted subsidies typically define eligibility around clinical criteria. Based on how similar subsidy models have worked in other therapeutic areas, qualifying criteria could include:
- A BMI at or above 30 (or 27 with a weight-related condition)
- Diagnosed comorbidities such as type 2 diabetes, cardiovascular disease, sleep apnea, or hypertension
- Prior documented attempts at lifestyle intervention without sustained results
This approach mirrors how Australia's Pharmaceutical Benefits Scheme (PBS) currently handles other chronic disease medications. It also reflects how Medicare and Medicaid discussions in the US are framing potential GLP-1 coverage expansions.
What "Targeted" Leaves Out
People seeking GLP-1 medications primarily for cosmetic weight loss or modest weight reduction without documented health risks would likely fall outside the scope of targeted subsidies. This is a meaningful distinction for patients to understand early, because it shapes realistic expectations about who benefits and when.
The Cost Reality Patients Are Facing Right Now
While the policy debate unfolds, patients are paying real money every month. In Australia, Ozempic is PBS-listed for type 2 diabetes but not for weight management, meaning patients using it off-label or using Wegovy for obesity pay full price or close to it. In the US, the picture is similarly patchy.
| Medication | Primary Approval | Typical Monthly Cost (No Coverage) | With Insurance or Subsidy (Where Available) |
|---|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes | $850-$1,000 USD / $100-$150 AUD (PBS) | As low as $25/month with manufacturer savings card (US) |
| Wegovy (semaglutide) | Chronic weight management | $1,300-$1,400 USD / $400+ AUD (no PBS listing) | Varies widely; many US plans still exclude it |
| Mounjaro (tirzepatide) | Type 2 diabetes | $1,000-$1,100 USD | Savings card available; coverage expanding slowly |
These figures underscore why the subsidy conversation is so charged. For many patients, the monthly cost of these medications exceeds a car payment.
The Case For and Against Targeted Coverage
This is genuinely a complex policy question, and it helps to understand both sides before forming an opinion or deciding how to advocate for yourself.
Arguments Supporting Targeted Subsidies
Obesity is now widely classified as a chronic disease, not a lifestyle failing. The clinical evidence for GLP-1 medications in high-risk populations is strong. The landmark SELECT trial, for example, showed that semaglutide reduced major cardiovascular events by 20% in people with obesity and existing heart disease, with no diabetes diagnosis required.
From a public health economics perspective, subsidizing effective treatment for a costly chronic disease can reduce downstream spending on hospitalizations, cardiovascular procedures, and diabetes complications. Governments in several countries have started making this calculation.
Arguments Against Universal or Broad Subsidies
The counterargument centers on cost and sustainability. GLP-1 medications are expensive, and unlike many drugs, patients typically need to stay on them indefinitely to maintain results. Covering them broadly could strain health budgets significantly, particularly if demand grows as expected.
There is also the question of prioritization. Health systems face competing demands, and some critics argue that funding high-cost drugs for weight management competes with resources for oncology, rare diseases, or primary care infrastructure.
What This Means If You Have Obesity-Related Health Conditions
If you have type 2 diabetes, a documented cardiovascular condition, or other obesity-related diagnoses, you are in the strongest position to benefit from targeted subsidies if and when they arrive. You also have the best case to make to your doctor and insurer right now.
Questions to Ask Your Doctor Today
You do not have to wait for policy changes to explore your options. These questions can help open a productive conversation:
- Do I meet clinical criteria for a GLP-1 medication based on my BMI and health history?
- Is Ozempic covered under my insurance for my diabetes or cardiovascular diagnosis?
- Would you document my obesity-related comorbidities to support a coverage appeal?
- Are there compounded or lower-cost alternatives I should consider in the interim?
Having a documented medical justification from your provider strengthens insurance appeals and, in markets like Australia, supports access to subsidized listings where they exist.
How Compounding and Telehealth Have Changed the Equation
While branded GLP-1 medications carry high price tags, the rise of telehealth providers and compounded semaglutide has created a parallel access pathway for many patients. Compounded semaglutide, prepared by licensed pharmacies and prescribed through telehealth platforms, has been available at significantly lower prices in the US.
However, the FDA has tightened rules on compounded semaglutide as branded drug shortages have eased. Compounded tirzepatide, the active ingredient in Mounjaro, is facing similar regulatory scrutiny. This means the compounding pathway is narrowing, making the subsidy and insurance coverage debate even more critical for patients who relied on it for affordability.
Checking the best GLP-1 providers can help you understand which platforms still offer compliant compounded options and which have transitioned to branded medication support, including cost assistance programs.
What Australia's Policy Push Signals for Global Access
The Novo Nordisk call for targeted subsidies in Australia is notable because Australia has a well-established precedent for evaluating drugs based on cost-effectiveness through its Pharmaceutical Benefits Advisory Committee (PBAC). When a drug is listed on the PBS, patient costs drop dramatically to a standard co-pay.
Wegovy has not been PBS-listed for weight management in Australia, leaving patients to pay the full market price. Novo Nordisk's advocacy signals that the company believes the clinical case is strong enough to warrant public funding, and it is investing political capital in making that argument.
If Australia moves toward targeted PBS listing for obesity-indication semaglutide, it could signal momentum in other markets. The UK's NHS is already piloting weight-loss drug access programs. The US Medicare expansion of GLP-1 coverage for cardiovascular risk, which took effect in 2024, is another sign of the direction policy is heading globally.
Patients in all of these markets benefit from staying informed, because coverage decisions that are made now will shape access and pricing for years.
How to Reduce Your Costs While Policy Catches Up
You likely cannot afford to wait for a subsidy that may take two to five years to materialize through full policy implementation. The good news is that there are meaningful ways to reduce costs today.
Manufacturer Savings Programs
Novo Nordisk offers savings cards in the US that can bring the cost of Ozempic down to as low as $25 per month for eligible commercially insured patients. Wegovy has a similar program. These do not apply to Medicare or Medicaid patients, but for those with employer-sponsored insurance, they can be significant.
Insurance Prior Authorization
If your insurer excludes GLP-1 medications, ask your doctor to submit a prior authorization with supporting documentation of your BMI, comorbidities, and previous interventions. Approval rates improve substantially when submissions are well-documented.
Provider and Cost Comparison
Not all telehealth providers charge the same for consultations, prescriptions, and follow-up care. Comparing platforms through a resource like the GLP-1 provider comparison tool can surface options you might not have considered.
Coupons and Discount Programs
Pharmacy discount programs and manufacturer coupons can reduce costs at the point of dispensing. The GLP-1 coupons page aggregates current savings options worth checking before each refill.
No waiting list. No insurance needed.
Frequently Asked Questions
What are targeted GLP-1 subsidies and who would qualify?
Targeted subsidies would fund GLP-1 medications for specific high-risk groups, typically people with a BMI of 30 or higher plus obesity-related conditions like type 2 diabetes or heart disease. They are not intended to cover everyone seeking weight loss.
Is Wegovy covered by insurance or government health programs?
Coverage for Wegovy varies significantly. In the US, many private insurers still exclude it, though some employer plans have added it. In Australia, it is not PBS-listed for weight management, meaning patients pay full price. Medicare in the US added coverage for cardiovascular risk patients in 2024.
How much does Ozempic cost without insurance?
Without insurance, Ozempic typically costs between $850 and $1,000 per month in the US. Novo Nordisk's savings card can reduce this to as low as $25 for eligible commercially insured patients, but the card does not apply to government insurance programs.
Will GLP-1 drug prices go down as subsidies expand?
Subsidies do not directly lower the list price of a drug. They reduce what the patient pays by having the government or insurer cover the difference. Actual price reductions would require separate negotiations or the entry of generic versions, which are years away for most GLP-1 medications.
Can I get compounded semaglutide now that the shortage is over?
The FDA has restricted compounded semaglutide as branded Ozempic and Wegovy have become more consistently available. Some pharmacies continue to compound it under specific exemptions, but the pathway has narrowed significantly. Check with a licensed telehealth provider for your current options.
What is the PBS and how does it affect GLP-1 access in Australia?
The Pharmaceutical Benefits Scheme (PBS) is Australia's government drug subsidy program. Drugs listed on the PBS are heavily subsidized, reducing patient cost to a standard co-pay of roughly $30 AUD. Ozempic is PBS-listed for type 2 diabetes, but Wegovy is not currently listed for weight management.
The Bottom Line: What This Debate Means for Your Decisions Now
The push for targeted GLP-1 subsidies is a meaningful development, and it signals that governments and manufacturers are increasingly acknowledging obesity as a serious medical condition that warrants public health investment. That is a shift from where the conversation was even five years ago.
But policy moves slowly. A subsidy proposal, even one with strong backing from a major pharmaceutical company, still has to pass through health technology assessment bodies, budget negotiations, and political cycles. Patients with real health needs today cannot put their treatment decisions on hold waiting for that process to conclude.
What You Can Do Right Now
If you have obesity-related health conditions, the strongest move you can make is to have a thorough conversation with your doctor that documents your clinical picture clearly. This serves two purposes: it positions you well for any future subsidy eligibility, and it gives you the documentation needed to pursue insurance coverage or prior authorization today.
If cost is the primary barrier, compare your options across providers and savings programs before assuming branded GLP-1 medications are out of reach. Many patients find that a combination of manufacturer savings, a supportive prescriber, and a well-chosen telehealth platform makes treatment financially manageable.
The subsidy debate is, ultimately, a signal that the medical and policy worlds are catching up to what clinical evidence has been showing for years. GLP-1 medications work for the right patients. The access question is still being answered, but momentum is building.
In the meantime, GLP-1.com is here to help you navigate costs, compare providers, and stay current on policy changes that affect your access. Check the best GLP-1 providers to find a platform that fits your needs, or visit the GLP-1 coupons page to find current savings on branded medications. As always, consult your physician before starting or changing any medication.